Aarti Drugs · NSE: AARTIDRUGS · BSE: 524348
Q4 FY22 results · Jan–Mar 2022
Aarti Drugs reported revenue from operations of ₹694.27 crore (up 38.4% from Q4 FY21) and net profit of ₹55.32 crore (up 7.1% from Q4 FY21) for Q4 FY22 (Jan–Mar 2022), on a consolidated basis.
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 694.27 | 501.75 | +38.4% | 634.80 | +9.4% |
| Other income | 2.96 | 0.97 | +205.2% | 6.66 | −55.6% |
| Total income | 697.23 | 502.72 | +38.7% | 641.46 | +8.7% |
| Profit before tax | 70.50 | 65.25 | +8.0% | 78.69 | −10.4% |
| Net profit for the period | 55.32 | 51.65 | +7.1% | 58.28 | −5.1% |
| Attributable to shareholders of the company | 55.34 | 51.65 | +7.1% | 58.29 | −5.1% |
| EPS, basic (₹) | 5.97 | 5.54 | +7.8% | 6.29 | −5.1% |
| Net margin (%) | 8.0 | 10.3 | 9.2 |
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 641.48 | 452.08 | +41.9% | 593.21 | +8.1% |
| Other income | 0.62 | 0.85 | −27.1% | 1.62 | −61.7% |
| Total income | 642.10 | 452.93 | +41.8% | 594.83 | +7.9% |
| Profit before tax | 67.00 | 63.24 | +5.9% | 75.35 | −11.1% |
| Net profit for the period | 53.00 | 50.24 | +5.5% | 55.85 | −5.1% |
| EPS, basic (₹) | 5.72 | 5.39 | +6.1% | 6.03 | −5.1% |
| Net margin (%) | 8.3 | 11.1 | 9.4 |
Consolidated
- Filed with BSE
- 10 May 2022, 16:55 IST
- Board meeting
- 09 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 10 May 2022, 16:55 IST
- Board meeting
- 09 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE